Wall Street analysts expect Aduro BioTech Inc (NASDAQ:ADRO) to post ($0.36) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Aduro BioTech’s earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.46). Aduro BioTech reported earnings of ($0.44) per share during the same quarter last year, which would suggest a positive year over year growth rate of 18.2%. The business is scheduled to issue its next earnings results on Wednesday, March 7th.
On average, analysts expect that Aduro BioTech will report full year earnings of ($1.28) per share for the current financial year, with EPS estimates ranging from ($1.39) to ($1.22). For the next financial year, analysts forecast that the firm will report earnings of ($1.28) per share, with EPS estimates ranging from ($1.66) to ($0.78). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Aduro BioTech.
Several research analysts have recently weighed in on the stock. HC Wainwright set a $18.00 price target on shares of Aduro BioTech and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Oppenheimer dropped their price target on shares of Aduro BioTech from $15.00 to $13.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 13th. BidaskClub cut shares of Aduro BioTech from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 3rd. Finally, Canaccord Genuity set a $30.00 price target on shares of Aduro BioTech and gave the stock a “buy” rating in a research note on Thursday, December 14th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $17.71.
Shares of Aduro BioTech (NASDAQ:ADRO) traded up $0.05 during trading on Monday, hitting $6.10. 886,973 shares of the stock traded hands, compared to its average volume of 538,847. The stock has a market cap of $467.69, a PE ratio of -4.49 and a beta of 3.01. Aduro BioTech has a 1-year low of $5.82 and a 1-year high of $14.05.
In other news, insider Stephen T. Isaacs sold 19,800 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $7.97, for a total transaction of $157,806.00. Following the sale, the insider now directly owns 190,321 shares in the company, valued at approximately $1,516,858.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Dirk G. Brockstedt sold 5,877 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $8.00, for a total transaction of $47,016.00. Following the sale, the executive vice president now owns 75,533 shares in the company, valued at $604,264. The disclosure for this sale can be found here. Insiders have sold a total of 205,176 shares of company stock worth $1,752,625 over the last 90 days. Insiders own 6.60% of the company’s stock.
Several hedge funds have recently made changes to their positions in ADRO. Harvard Management Co. Inc. bought a new stake in shares of Aduro BioTech during the 3rd quarter valued at $69,418,000. JPMorgan Chase & Co. raised its position in shares of Aduro BioTech by 283.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock valued at $4,244,000 after purchasing an additional 275,295 shares during the period. Citadel Advisors LLC bought a new stake in shares of Aduro BioTech during the 4th quarter valued at $1,309,000. Baillie Gifford & Co. raised its position in shares of Aduro BioTech by 30.8% during the 3rd quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock valued at $5,891,000 after purchasing an additional 130,390 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Aduro BioTech by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock valued at $28,637,000 after purchasing an additional 129,079 shares during the period. Hedge funds and other institutional investors own 45.14% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Expect Aduro BioTech Inc (ADRO) to Announce -$0.36 EPS” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/17/zacks-brokerages-expect-aduro-biotech-inc-adro-to-announce-0-36-eps.html.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Get a free copy of the Zacks research report on Aduro BioTech (ADRO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.